Announcements Trials
Browse Landscape

Phase

Phase 1/2 3Phase 1 3Phase 2 2

Status

Completed 2Terminated 1

Sponsor Class

OTHER 1NIH 1INDUSTRY 1

Study Type

Interventional 3

Sponsor

Cancer Type

Tumor-Agnostic 1Genitourinary 1Gastrointestinal 1

Conditions

Rectal Neoplasms 1Neoplasms 1Colorectal Neoplasms 1Colonic Neoplasms 1Carcinoma, Renal Cell 1

Interventions

pembrolizumab 409Cyclophosphamide 398Carboplatin 307Gemcitabine 286Nivolumab 276Paclitaxel 274Cisplatin 252Radiotherapy 225Dexamethasone 209Bevacizumab 207fludarabine 195Docetaxel 186Rituximab 183Capecitabine 171Oxaliplatin 158Lenalidomide 157Fluorouracil 152Temozolomide 138Cytarabine 135Etoposide 128Irinotecan 124Cetuximab 123fludarabine phosphate 121Injections 118venetoclax 116Ipilimumab 115Doxorubicin 114Azacitidine 108130-nm albumin-bound paclitaxel 108Pemetrexed 107

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Phase 1/2 × etaracizumab × Clear all
NCT00684996 2014-05-15

Bevacizumab With or Without MEDI-522 in Treating Patients With Unresectable or Metastatic Kidney Cancer

National Cancer Institute (NCI)

Phase 1/2 Terminated
5 enrolled 7 charts
Genitourinary

Carcinoma, Renal Cell

NCT00027729 2013-06-05

Monoclonal Antibody Therapy in Treating Patients With Advanced Colorectal Cancer

Memorial Sloan Kettering Cancer Center

Phase 1/2 Completed
Gastrointestinal

Colonic Neoplasms, Rectal Neoplasms, Colorectal Neoplasms

NCT00284817 2008-05-29

Phase I Study of MEDI522 in Patients With Irinotecan-Refractory Advanced Colorectal Cancer

MedImmune LLC

Phase 1/2 Completed
17 enrolled
Tumor-Agnostic

Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡